Viracta Therapeutics Winds Down Operations, Terminates Employees

Dow Jones

02/06

By Sabela Ojea

Viracta Therapeutics plans to wind down operations and has terminated its employees.

The clinical-stage precision oncology company on Wednesday said that it named Chief Executive Craig Jalbert, who took over the top job last March, as the sole member of the board to implement the wind down.

The company said that it's also exploring potential strategic alternatives for its development programs.

The decision comes about a month after the company said its board had initiated a process to explore strategic options, and that it had decided to close a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, to maximize its cash runway.

In November, the company said it was cutting its workforce and reducing the size of the board to six from 10.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

February 05, 2025 17:25 ET (22:25 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2509250337"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509250337\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509250337?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509250337","market":"us","top_or_hot":-1,"title":"Viracta Therapeutics Winds Down Operations, Terminates Employees","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Viracta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plans to wind down operations and has terminated its employees. \n</p>\n<p>\n  The clinical-stage precision oncology company on Wednesday said that it named Chief Executive Craig Jalbert, who took over the top job last March, as the sole member of the board to implement the wind down. \n</p>\n<p>\n  The company said that it's also exploring potential strategic alternatives for its development programs. \n</p>\n<p>\n  The decision comes about a month after the company said its board had initiated a process to explore strategic options, and that it had decided to close a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, to maximize its cash runway. \n</p>\n<p>\n  In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 05, 2025 17:25 ET (22:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viracta Therapeutics Winds Down Operations, Terminates Employees</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViracta Therapeutics Winds Down Operations, Terminates Employees\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-06 06:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Viracta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plans to wind down operations and has terminated its employees. \n</p>\n<p>\n  The clinical-stage precision oncology company on Wednesday said that it named Chief Executive Craig Jalbert, who took over the top job last March, as the sole member of the board to implement the wind down. \n</p>\n<p>\n  The company said that it's also exploring potential strategic alternatives for its development programs. \n</p>\n<p>\n  The decision comes about a month after the company said its board had initiated a process to explore strategic options, and that it had decided to close a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, to maximize its cash runway. \n</p>\n<p>\n  In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 05, 2025 17:25 ET (22:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2509250337","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509250337","pubTimestamp":1738794300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Viracta Therapeutics plans to wind down operations and has terminated its employees.The clinical-stage precision oncology company on Wednesday said that it named Chief Executive Craig Jalbert, who took over the top job last March, as the sole member of the board to implement the wind down.The company said that it's also exploring potential strategic alternatives for its development programs.The decision comes about a month after the company said its board had initiated a process to explore strategic options, and that it had decided to close a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, to maximize its cash runway.In November, the company said it was cutting its workforce and reducing the size of the board to six from 10.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Viracta Therapeutics缩减业务并解雇员工","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"VIRX":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Viracta Therapeutics plans to wind down operations and has terminated its employees. \n\n\n  The clinical-stage precision oncology company on Wednesday said that it named Chief Executive Craig Jalbert, who took over the top job last March, as the sole member of the board to implement the wind down. \n\n\n  The company said that it's also exploring potential strategic alternatives for its development programs. \n\n\n  The decision comes about a month after the company said its board had initiated a process to explore strategic options, and that it had decided to close a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, to maximize its cash runway. \n\n\n  In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 05, 2025 17:25 ET (22:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}